Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 29 Oct 2026 16:02 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 29 Oct 2026 14:32 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 29 Oct 2026 12:45 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 29 Oct 2026 10:38 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Oct 2026 10:38 CET |
NAVAMEDIC | Finansiell kalender | 20103015 Pharmaceuticals | Annen informasjonspliktig regulatorisk informasjon |
| 29 Oct 2026 07:01 CET |
NAVAMEDIC | Navamedic ASA: Profitability improvement driven by product mix and cost discipline despite decreased revenue | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 29 Oct 2026 07:00 CET |
NAVAMEDIC | Navamedic ASA: Lønnsomhetsforbedring drevet av produktmiks og kostnadsdisiplin til tross for lavere inntekter | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 26 Oct 2026 09:45 CET |
NAVAMEDIC | Navamedic ASA: Invitation to presentation of third quarter 2026 results | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Oct 2026 08:45 CEST |
NAVAMEDIC | Prolongation of Mysimba® distribution agreement | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 02 Sep 2026 16:50 CEST |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 14 Aug 2026 07:00 CEST |
NAVAMEDIC | Navamedic ASA: Vekst og tosifret justert EBITDA-margin i Q2 og første halvår 2026 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 14 Aug 2026 07:00 CEST |
NAVAMEDIC | Navamedic ASA: Growth and double-digit adjusted EBITDA margin in Q2 and first half 2026 | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 10 Aug 2026 08:31 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to presentation of second quarter and first half year 2026 results | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Jun 2026 17:15 CEST |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 16 Jun 2026 07:57 CEST |
NAVAMEDIC | Navamedic ASA: Change in leadership | 20103015 Pharmaceuticals | Inside information |
| 21 May 2026 15:27 CEST |
NAVAMEDIC | Navamedic launches Virono®- the first single-dose over-the-counter cold sore tablet | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 20 May 2026 12:45 CEST |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 19 May 2026 13:22 CEST |
NAVAMEDIC | Flaggemelding Navamedic ASA | 20103015 Pharmaceuticals | Flagging |
| 18 May 2026 16:00 CEST |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 15 May 2026 17:21 CEST |
NAVAMEDIC | Flaggemelding NAVA | 20103015 Pharmaceuticals | Flagging |
| 15 May 2026 11:52 CEST |
NAVAMEDIC | Flaggemelding Navamedic ASA | 20103015 Pharmaceuticals | Flagging |
| 23 Apr 2026 16:07 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Apr 2026 07:00 CEST |
NAVAMEDIC | Navamedic ASA: Steady performance and continued product launch in Q1 2026 | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 23 Apr 2026 07:00 CEST |
NAVAMEDIC | Navamedic ASA: Stabil drift og fortsatt produktlansering i første kvartal 2026 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 20 Apr 2026 08:32 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to presentation of first quarter 2026 results | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Apr 2026 17:21 CEST |
NAVAMEDIC | Navamedic ASA: Recommendation of the nomination committee for the Annual General Meeting on 23 April 2026 | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 Mar 2026 12:00 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Mar 2026 13:11 CET |
NAVAMEDIC | Annual Report 2025 | 20103015 Pharmaceuticals | Annual financial and audit Reports |
| 27 Feb 2026 14:38 CET |
NAVAMEDIC | Flaggemelding NAVA | 20103015 Pharmaceuticals | Flagging |
| 27 Feb 2026 14:28 CET |
NAVAMEDIC | Flaggemelding Navamedic ASA | 20103015 Pharmaceuticals | Flagging |
| 27 Feb 2026 13:05 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 12 Feb 2026 07:00 CET |
NAVAMEDIC | Navamedic ASA: Strong growth and important product launch in Q4 2025 | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 12 Feb 2026 07:00 CET |
NAVAMEDIC | Navamedic ASA: Sterk vekst og viktig produktlansering i fjerde kvartal 2025 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 09 Feb 2026 09:19 CET |
NAVAMEDIC | Navamedic ASA: Invitation to presentation of fourth quarter 2025 results | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Jan 2026 14:01 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Jan 2026 12:35 CET |
NAVAMEDIC | Navamedic ASA: Minutes of Extraordinary General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Dec 2025 08:23 CET |
NAVAMEDIC | Grete Roede og Navamedic lanserer nytt vektreduksjonskonsept: Lettere steg | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 18 Dec 2025 08:48 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Dec 2025 08:00 CET |
NAVAMEDIC | Navamedic ASA: Notice of extraordinary general meeting on 7 January 2026 | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Dec 2025 13:00 CET |
NAVAMEDIC | Oslo, December 9, 2025 - Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson's Care with Simplified and Precise Dosing for Personalized Treatment | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 08 Dec 2025 07:33 CET |
NAVAMEDIC | Navamedic ASA: Utnevnelse av Finansdirektør | 20103015 Pharmaceuticals | Annen informasjonspliktig regulatorisk informasjon |
| 08 Dec 2025 07:33 CET |
NAVAMEDIC | Navamedic ASA: Appointment of CFO | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Nov 2025 17:05 CET |
NAVAMEDIC | Navamedic ASA: Resignation of CFO | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Oct 2025 07:00 CET |
NAVAMEDIC | Navamedic ASA: Double digit growth in the 3rd quarter, 2025 | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 28 Oct 2025 07:00 CET |
NAVAMEDIC | Navamedic ASA: Tosifret vekst i tredje kvartal 2025 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 24 Oct 2025 17:56 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2025 3rd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Oct 2025 11:22 CEST |
NAVAMEDIC | Navamedic ASA: Navamedic extends its business into Germany together with Evolsin Medical | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 15 Oct 2025 13:46 CEST |
NAVAMEDIC | NOTIFICATION OF MAJOR HOLDINGS | 20103015 Pharmaceuticals | Major shareholding notifications |
| 14 Oct 2025 14:38 CEST |
NAVAMEDIC | Flaggemelding NAVA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 13 Oct 2025 18:26 CEST |
NAVAMEDIC | Navamedic ASA - New share capital registered | 20103015 Pharmaceuticals | Total number of voting rights and capital |